fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

IMV 2015 Debate: Professors Faith Davies, Gareth Morgan (both UAMS) and Sagar Lonial (Atlanta) discuss the importance of combination therapy. Professor Faith Davies from UAMS and Professor Shaji Kumar from Mayo Clinic faced one another in a debate over the respective benefits of combination therapy and sequential therapy in MM…

Written by | 13 Nov 2015

Specialists in the MM field are in the enviable position of having lots of different treatment options available – the challenge is how to integrate these into the… read more.

IMV 2015: New diagnostic criteria for multiple myeloma

Written by | 13 Nov 2015

Multiple myeloma is unique amongst cancers in that the diagnosis is made by the clinician, not the pathologist. The pathologist merely states that the patient has a clonal… read more.

IMV 2015: Highlights of the International Myeloma Workshop, 23-26 September, Rome.

Written by | 13 Nov 2015

IMW President, Professor Antonio Palumbo (Torino, Italy) gives his highlights, along with Dr Noopar Raje  (Boston, USA) , Professor Faith Davies, (Little Rock, USA) and Professor Paul Richardson (Boston, USA).

EMA Highlights: Green light for new medicines

Written by | 13 Oct 2015

by Gary Finnegan: The European Medicines Agency’s key committee approved a total of 19 new medicines at its meeting in late September – the highest number of products… read more.

Video Interview and editorial from the BSH 2015: Professor Graham Jackson discusses the journey from despair to hope in multiple myeloma. Click on the image for interview and editorial.

Written by | 1 Jun 2015

Graham Jackson, Professor of Clinical haematology, Newcastle upon Tyne and former president of the British Society for Haematology (BSH). Article by Christine Clark: In the 1970s the prospect… read more.

Video Interview from the BSH 2015 Annual Meeting: Professor Graham Jackson gives his opinion on the controversial issue of whether we are nearing a cure for myeloma. Click on the image to hear interview.

Written by | 29 May 2015

Professor Graham Jackson, Royal Victoria Infirmary, Newcastle-Upon-Tyne, UK.

WTC Report 2014: Update on worldwide causes of morbidity and mortality in living donor liver transplantation

Written by | 9 Sep 2014

By Allan M Concejero et al, Kaohsiung Chang Gung Memorial Hospital, Taiwan.  Increased use of living donors for liver transplantations has meant an increase in donor complications and… read more.

Press Release: Emerging data from CLL10 presented at ASH suggests Levact® (bendamustine) and rituximab as new treatment option for fit elderly CLL patients

Written by | 7 Feb 2014

New interim analysis study findings presented for the first time today at the 55th American Society of Hematology (ASH) Annual Meeting in New Orleans suggest bendamustine and rituximab… read more.

Green light for new medicines

Written by | 29 Apr 2013

EMA Highlights by Gary Finnegan – The EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended the granting of marketing authorisations for several new products.

ASH 2012 Report – Novel therapeutic agents provide hope for patients with hard-to-treat blood disorders

Written by | 21 Dec 2012

Encouraging safety and efficacy data on novel and emerging therapies presented at the 54th Annual Meeting of the American Society of Haematology (ASH) signal an important step forward… read more.

ASH 2012 Report – New multiple myeloma drug shows promise in treating people with advanced disease

Written by | 21 Dec 2012

Therapy may be new option for hard-to-treat blood cancer.

ASH 2012 Report – New results support bendamustine-rituximab (B-R) combination as first-line treatment in patients with (iNHL) and (MCL)

Written by | 21 Dec 2012

Data demonstrate superior patient outcomes with B-R in first-line treatment of iNHL and MCL, compared with current standard of care.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.